Ananda Developments Plc Regulatory News (ANA.PL)

14 May 2024

ANANDA DEVELOPMENTS PLC

("Ananda" or the "Company")

Ananda Presentation to LSX Conference 2024

Ananda Developments plc (AQSE: ANA), a company focused on becoming a leading provider of CBD-based medicines for chronic inflammatory pain conditions, recently presented to life science industry leaders at the 10th LSX World Congress in London.

The LSX World Congress is the leading partnering, strategy and investment event in Europe for life science executives, offering networking opportunities and discussions on the latest industry trends and innovations.

Jeremy Sturgess-Smith, Ananda Finance Director, delivered a comprehensive presentation to potential investors and other industry leaders, showcasing the Company's progress in developing patent pending CBD formulations as regulated drugs for chemotherapy induced peripheral pain and endometriosis.

Ananda CEO Melissa Sturgess commented "CBD is a multi-modal molecule and shows great potential for treating people with chronic indications at a time when the NHS is overwhelmed and we have many people unable to go to work. We believe our drug development is happening just at the right time."

The presentation has been uploaded on Ananda's website and can be found via the following link: https://investors.anandadevelopments.com/activity-updates

About Ananda Developments

Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.

For further information on the Company visit https://anandadevelopments.com/ or sign up at https://investors.anandadevelopments.com/s/a66906.

https://investors.anandadevelopments.com/link/7eXQkr